Skip to navigation

ASTON/Montag & Caldwell Balanced Fund

CUSIP 00078H27300078H265
Share Class Inception 11/2/199412/31/1998
Gross Exp Ratio (%) 1.591.34
Net Exp Ratio (%) 1.351.10
30 Day Yield (02/28/15) 0.29 0.39
NAV Change (%) 0.30 0.30
Dividend Frequency Quarterly
Benchmark S&P 500/Barclays US Gov Cr 40
Morningstar Category Moderate Allocation

Overall Morningstar Rating

ASTON/Montag & Caldwell Balanced  Shares received a Morningstar rating.

Among 744 Moderate Allocation funds derived from a weighted average of the Fund’s 3-, 5- and 10-year risk-adjusted returns as of 1/31/15.

Portfolio Managers

Ronald Canakaris, CFA
Ronald Canakaris, CFA

Ronald Canakaris, CFA

Ronald Canakaris, CFA

Mr. Canakaris is the Chairman and Chief Investment Officer of Montag & Caldwell LLC, and has been the Lead Portfolio Manager of the Fund since its inception in November 1994. He joined the firm in 1972 as a portfolio manager and research analyst. He has a BS and BA from the University of Florida, and holds the Chartered Financial Analyst designation.

Helen M. Donahue, CFA
Helen M. Donahue, CFA

Helen M. Donahue, CFA

Helen M. Donahue, CFA

Ms. Donahue is a portfolio manager of equities and fixed income at Montag & Caldwell, and has been a Co-Portfolio Manager of the Fund since February 2013. She joined in 1997 and has more than 20 years of investment industry experience. Prior to joining Montag & Caldwell, she served as an Assistant Vice President and fixed income portfolio manager for Legg Mason Capital Management. Ms. Donahue holds the Chartered Financial Analyst designation.

Investment Strategy

The ASTON/Montag & Caldwell Balanced Fund invests primarily in a combination of equity, fixed-income, and short-term securities, with typically 50% to 70% of assets devoted to stocks and at least 25% to fixed-income to provide a stable flow of income.

If you are an investment professional, login or register here for access to Aston’s research content. Discover the unique qualities that differentiate our Subadvisers at both the firm and strategy levels.  


The Fund seeks long-term total return.

Risk Considerations

The Fund is subject to stock and bond risk, and its value can decline through either market volatility or a rise in interest rates.

Fund Stats (as of 12/31/14) N SharesI Shares
Origin Of Information FactsetFactset
Sales Load NoneNone
Total Net Assets (3/27/15)$20,529,605.77$1,764,232.73
Turnover 27%27%
Minimum Investment 2,5001,000,000
Alpha (3 yr.) -1.11-1.02
Beta (3 yr.) 0.560.56
R-Squared (3 yr.) 79.8779.78
Standard Dev (3 yr.) 5.685.69
Sharpe Ratio (3 yr.) 1.681.69
Current Wtd Average P/E (trailing) N/AN/A
Current Wtd Average P/B (trailing) N/AN/A
Median Mkt Cap ($Mil) N/AN/A
Average Wtd Coupon 3.303.30
Effective Maturity 6.496.49
Sector Breakdown (as of 2/28/15)
Corporate Bonds
Health Care
Consumer Staples
U.s. Government Obligations
Information Technology
Consumer Discretionary
Cash Equivalents & Other
Mortgage-backed Securities
Top 10 Holdings (as of 2/28/15)
CompanyTickerCUSIPNumber of SharesMarket Value% of Net Assets
PEPSICO INC PEP 713448108 6,720 $665,145.60 2.92%
MCKESSON CORP MCK 58155Q103 2,900 $663,230.00 2.92%
VISA INC V 92826C839 2,217 $601,494.27 2.64%
MONDELEZ INTERNATIONAL INC MDLZ 609207105 15,750 $581,726.25 2.56%
GILEAD SCIENCES INC GILD 375558103 5,600 $579,768.00 2.55%
BIOGEN IDEC INC BIIB 09062X103 1,333 $545,983.47 2.40%
ABBOTT LABORATORIES ABT 2824100 11,250 $532,912.50 2.34%
STARBUCKS CORP SBUX 855244109 5,300 $495,470.50 2.18%
THERMO FISHER SCIENTIFIC INC TMO 883556102 3,800 $494,000.00 2.17%
ALLERGAN INC/UNITED STATES AGN 18490102 2,063 $480,142.62 2.11%
Past performance does not guarantee future results. Investment return and principal value of mutual funds will vary with market conditions, so that shares, when redeemed, may be worth more or less than their original cost.

As the fund is actively managed, the securities as presented may not represent the current or future composition of the portfolio.

Designed and created by DDM Marketing & Communications.